Trust Co. of Vermont boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 44,025 shares of the biopharmaceutical company’s stock after buying an additional 1,644 shares during the period. Trust Co. of Vermont’s holdings in Gilead Sciences were worth $2,990,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Hall Laurie J Trustee boosted its position in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares in the last quarter. Cable Hill Partners LLC boosted its position in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 541 shares in the last quarter. Dubuque Bank & Trust Co. boosted its position in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares in the last quarter. Webster Bank N. A. boosted its position in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 624 shares in the last quarter. Finally, Thomas J. Herzfeld Advisors Inc. bought a new position in Gilead Sciences during the fourth quarter worth $143,000. 74.03% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 71.15 on Tuesday. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $88.85. The firm has a market cap of $92.97 billion, a PE ratio of 7.52 and a beta of 1.20. The firm’s 50-day moving average is $66.03 and its 200-day moving average is $68.95.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.18 by $0.02. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.66 billion. Gilead Sciences had a return on equity of 76.64% and a net margin of 43.42%. Equities analysts expect that Gilead Sciences, Inc. will post $8.37 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Thursday, June 29th. Investors of record on Friday, June 16th were given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.92%. The ex-dividend date was Wednesday, June 14th. Gilead Sciences’s dividend payout ratio is currently 21.99%.
GILD has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Gilead Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 11th. William Blair restated an “outperform” rating on shares of Gilead Sciences in a research report on Friday, June 16th. Jefferies Group LLC restated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, April 6th. Morgan Stanley restated an “equal weight” rating on shares of Gilead Sciences in a research report on Tuesday, July 11th. Finally, Credit Suisse Group restated an “outperform” rating and set a $79.00 price objective on shares of Gilead Sciences in a research report on Friday, May 5th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, fifteen have issued a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $80.24.
In related news, Director John Francis Cogan sold 9,943 shares of the company’s stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total transaction of $668,666.75. Following the sale, the director now directly owns 47,562 shares of the company’s stock, valued at approximately $3,198,544.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the sale, the executive vice president now directly owns 102,988 shares in the company, valued at $7,318,327.28. The disclosure for this sale can be found here. Over the last three months, insiders have sold 88,276 shares of company stock worth $6,230,610. Corporate insiders own 1.30% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.